简介：'biotech' tag rss syndication from seekingalpha.com

原站：http://seekingalpha.com/sector/biotech

“Biotech Sector and Stocks Analysis from Seeking Alph”的内容更新

累计：3587 篇（自 2008-12-10 起）

更新：约3篇/天，最后更新313 天前

Biotech Sector and Stocks Analysis from Seeking Alpha

Vertex Pharmaceuticals: Telaprevir a Likely Lock for

bert wilkison submits:on 04/07/11, vertex pharmaceuticals (vrtx) made headlines when it announced that one of its long time collaborators, cystic fibrosis foundation therapeutics, agreed to provide up to $75m over the next five years to support research and development for some of vertex's early stage product candidates in exchange for entitlement to roy... (306 天前)

http://inezha.com/w/n041hk6j

Biotech Sector and Stocks Analysis from Seeking Alpha

Why Provenge Could Be a $10 Billion Drug for Dendreo

saul kerpelman submits:on march 10, 2011 a federal judge in the southern district of new york issued a ruling in a case involving medicare coverage for "off label" drugs that may come to have tremendous importance for cancer treatments, and specifically for dendreon and its recently fda-approved, revolutionary treatment for prostate cancer, provenge. the... (306 天前)

http://inezha.com/w/b9ftzk6a

Biotech Sector and Stocks Analysis from Seeking Alpha

Momenta Set Up for Profitable 2011

m.e. garza submits: by patrick crutcher with most smallcap biotech companies, investors don't have high expectations for significant revenue from pipeline assets. however, momenta pharmaceuticals (nasdaq: mnta) bucks that trend entirely. considering the size of momenta's revenue stream, we're frankly amazed that they are valued around $750 million. in ... (306 天前)

http://inezha.com/w/x4pr8k6z

Biotech Sector and Stocks Analysis from Seeking Alpha

Sunesis Signs Deal, Improves Pipeline Prospects

jason chew submits: south san francisco based sunesis (snss) announced a license agreement on april 5 with millennium pharmaceuticals to develop its pan-raf kinase inhibitor. under the terms of this deal, sunesis received $4 million upfront and potentially $60 million in milestones as well as royalties. millennium will pay for all costs of the phase i tr... (306 天前)

http://inezha.com/w/ylfpaj6w

Biotech Sector and Stocks Analysis from Seeking Alpha

SuperGen: Merger Is A Step In The Right Direction

james stocklasar thomas jr. submits:on 17 march, i wrote that "supergen: flush with cash, but drug pipeline is anemic" sincerely believing that the best way forward for the cash-flush supergen (supg) was to either in-license a later stage drug candidate, or do as they have, execute a merger. as a follow-up, i think this merger is good news for both super... (306 天前)

http://inezha.com/w/034wdj61

Biotech Sector and Stocks Analysis from Seeking Alpha

6 Cash Rich Biotech Stocks With Catalysts

rougemont submits: all of these biotech companies have very substantial amounts of cash or cash equivalents on their balance sheets. they also have either little to no debt. biotechs typically burn through cash and when they don't have enough on hand or have too much debt, it can lead to trouble quick, especially if a new drug doesn't pan out as promised... (306 天前)

http://inezha.com/w/98powj6f

Biotech Sector and Stocks Analysis from Seeking Alpha

Biotech: Top 3 Analyst Picks

elan corporation plc (nyse: eln), protalix biotherapeutics inc. (amex: plx) and intermune inc. (nasdaq: itmn) are three top analyst stock picks made during today’s session. elan upgraded and seen as potential takeover target elan corporation (nyse: eln), a neuroscience-based biotechnology company, was upgraded to outperform with a $10.00 per share... (306 天前)

http://inezha.com/w/xarzc66e

相关订阅源